Bolsas y Mercados Españoles
Company
search
GRIFOLS, S.A.
AddressCL JESUS Y MARIA 6, 08022 BARCELONA 
Listed Capital119,603,705.00 Euros



GRIFOLS CLASE B
ISINES0171996095 TickerGRF.P Nominal0.05 MarketContinuous Market Admitted Capital13,071,255.50 Euros 

Last prices
DateHourCloseRef.% Dif.LastHighLowAvg.VolumeTurnover
20/10/2017Close18.210018.11000.5518.210018.450018.055018.148214,949271,297.01

Last pay
TypeEx-datePayment DateConcept
Dividend30/05/201701/06/2017Final 2016

Last split
DateEquivalence
04/01/20162 x 1

Last reverse split
DateEquivalence
 

Last capital increase
PeriodProportionType
22/04/2013 - 22/04/201368 x 10,000Premium


 2017
until 20/10
2016201520142013
Capitalisation *
(thousands of euros)
4,760,5513,974,9693,910,2663,666,4873,383,494
Shares
(x 1,000)
261,425261,425130,713130,713130,713
Period Close Price
(euros)
18.210015.205014.957514.025012.9425
Period Last Price
(euros)
18.210015.205014.957514.025012.9425
Period High Price
(euros)
20.455015.650016.845017.300013.1975
Period Low Price
(euros)
15.050012.700012.500011.30259.0225
Volume
(thousands of shares)
16,22450,06472,042102,65953,329
Turnover
(thousands of euros)
286,509705,5411,072,8551,505,921589,606

Profile

Grifols, with presence in more than 100 countries, is a global pharmaceutical company specializing in the Hemotherapy sector, the medical discipline that treats disease using blood components. The company’s class A shares have been listed on the Spanish Stock Exchange (MCE:GRF) since 2006 and have been part of the Ibex-35 since 2008.  In 2011, the company listed non-voting class B shares on the Mercado Continuo (MCE:GRF.P) and in NASDAQ-United States via ADRs  (NASDAQ: GRFS). 

Grifols is the third company worldwide in plasma protein therapies, in terms of capacity after the recent purchase of Talecris, with a balanced and diversified range of products.  In upcoming years, the company will strengthen its leadership in the industry as a vertically integrated company, as a result of on-going investment plans. Grifols is the world leader in plasma collection with 150 plasma donor centers in the United States to ensure a continued and reliable supply of human plasma for the production of plasma therapies. In terms of production capacity (fractionation), Grifols owns and operates several plants in Spain and the United States that allow it to respond to the growing market demand. Grifols’ sustained growth will be supported by a strong presence in the United States, Canada and Europe.

You can find more information about Grifols on www.grifols.com

Source: Issuing company.
21/10/2017 00:08:14

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Follow us in:
Copyright © Bolsas y Mercados Españoles 2017